The 2nd day of National Cancer Institute symposium celebrating Steven Rosenberg is off to a strong start ✨on a side note, a Cancer Discovery paper by the Rosenberg group has been cited these 2 days, so here it is 😊👉🏻 aacrjournals.org/cancerdiscover…

Amazing: 2 patients spontaneously shared their incredible journeys at National Cancer Institute Clinical Center, one of whom was a patient of Steven Rosenberg, and Dr. Kimryn Rathmell emphasized the crucial role of basic-clinical crosstalk in helping patients, as exemplified by Steven Rosenberg

I had the honor of presenting @NCIResearchCtr’s Dr. Steven Rosenberg with a milestone award for 50 years of excellent service to National Cancer Institute. His pioneering work in immunotherapy has touched lives, inspired researchers, and transformed our field. Congratulations, Steven!

Thrilled to introduce "The Epigenetic Hallmarks of Cancer", our Cancer Discovery Cancer Discovery AACR article. A team work by Mark Dawson Mark Dawson, Cigall Kadoch Cigall Kadoch, Feyruz Rassool, Peter Jones, Steve Baylin and yours truly. Enjoy! aacrjournals.org/cancerdiscover…

Excited to attend the inaugural AACR Grantee Summit to hear about the exciting work of AACR grantees and participate in a roundtable discussion on how to publish papers! Did you know that AACR has funded over $500 million of research grants over the past 30 years? #AACRgrants

The Fifth National Cancer Institute #RAS Initiative Symposium (and my third!) is starting with Dr. Kimryn Rathmell starting things off with her thoughts on the importance of the RAS Initiative in fostering collaborations/inspiration: also, she’s going to stay for the first day, so meet her if you can!

Andrew Aguirre Dana-Farber is speaking about the identification of RAS G12C inhibitor resistance mechanisms at National Cancer Institute #RAS Initiative Symposium, including work he and colleagues recently published 👉🏻 aacrjournals.org/cancerdiscover…

Andrew Aguirre discusses potential KRASi combinations with other modalities including immunotherapy for PDAC and cites a recent paper by Dr. Ron DePinho and colleagues as an example 👉🏻 aacrjournals.org/cancerdiscover…

Mallika Singh of Revolution Medicine is describing the strategy used to generate exciting pan-RAS RevMed inhibitors: check out the preclinical evaluation and characterization of RMC-6236 (includes patient data!) 👉🏻 aacrjournals.org/cancerdiscover…

Robert Vonderheide Penn Medicine - Abramson Cancer Center suggests that KRAS inhibitors are immunotherapies and describes the work describing the effects of KRASi on the tumor immune contexture that Ben Stanger, he, and colleagues published last year 👉🏻 aacrjournals.org/cancerdiscover…

Day 2 of ⁦National Cancer Institute⁩ #RAS Initiative kicks off with ⁦Margaret Foti, PhD, MD (hc)⁩ giving an overview of the close relationship between AACR and the #RAS community as well as the goals and vision that the AACR has for promoting advances in this community

Andy Stephen @FredNatLab is speaking at National Cancer Institute #RAS Initiative about the allosteric regulation of SOS, including the evaluation of the REM domain: since pictures are strictly forbidden, here is a completely accurate depiction of said domain 👉🏻

.⁦AACR⁩ ready for more science at ⁦National Cancer Institute⁩ #RAS Initiative!

It’s the final day of National Cancer Institute #RAS Initiative, and for the first time there is a pediatric cancer-focused session: there is a growing body of literature on Ras in pediatric cancer, as Elliot Steiglitz UCSF Helen Diller Family Comprehensive Cancer Ctr shows 👉🏻 aacrjournals.org/cancerdiscover…

Excited to share our new paper out in Cancer Discovery! We developed GCOs—glioblastoma cells grown in human cortical organoids—and used scRNA-seq to show their increased fidelity to patient cell states. Plus, we found tumor cells transfer malignant mRNAs to non-malignant cells!

Senior Editor I-Mei Sui, PhD is at the AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation. #aacrLBx24 Connect with her before or after the meeting to discuss your research and publishing opportunities! I-Mei (Emay) Siu

Excited to be here! If you’re here and want to ask about Cancer Discovery, come join me for breakfast 🥞

Jillian Phalen ⁦Johns Hopkins Kimmel Cancer Center⁩ presenting just-published work on DELFI (cell-free fragmentome/proteins) for the early detection of ovarian cancer #aacrLBx24 aacrjournals.org/cancerdiscover…

Our collaboration with yardena samuels and @NCIEytanRuppin is out in Cancer Discovery ! Why do genetically similar tumors show dramatic differences in immune rejection? We used temporal single-cell genomics of rejection + CRISPR screens to identify a potential cause related to

👏🏻👏🏻👏🏻